Just 30 percent of Americans living with HIV have the virus in check, putting others at risk of infection, U.S. health officials said yesterday. The report by the U.S. Centers for Disease Control and Prevention (CDC) found that 840,000 of the 1.2 million people infected with HIV in 2011 were not consistently taking anti-HIV drugs that keep the virus suppressed at very low levels.
26 November 2014 | Reuters
Sizwe Nzima was a high school student in Cape Town, South Africa, when he would pick up the medicine for his HIV-positive grandparents, who had difficulty traveling to the clinic themselves. Because of the long lines, Nzima usually waited hours and often made multiple trips to the clinic before and after school. So there he was, sitting on a hard wooden bench at the clinic one day about four years ago, when he had an idea: Why not start an HIV medicine delivery service?
18 November 2014 | NPR (blog)
FDC drug development is evolving rapidly as the industry gains experience in manufacturing them and ushering them through the review process. The laws have changed towards a more favorable marketing climate. And finally, it is clear that FDCs are more than a way to improve adherence—though that will always be a prominent consideration. FDCs can shift the standard of care towards a more tolerable, patient-friendly, value-oriented approach to treatment, and in the final analysis, that approach to development bodes well for companies, payers, and most importantly, patients.
07 November 2014 | BioPharma Dive
There is no magic formula for achieving 10 years of continuous viral load suppression on antiretroviral therapy in people living with HIV -- even perfect adherence didn't improve the chances of continuously suppressed viral loads, according to a poster analysis of the U.S. Military HIV Natural History Study (NHS) cohort presented at IDWeek 2014 in Philadelphia.
29 October 2014 | TheBody.com
While making medications free can remove barriers to access for individuals who cannot pay for treatment, data suggest that for most people accessing care in industrialized countries, "making medications available for free or low cost will not solve problems with medication non-adherence," according to a presentation by Kevin Volpp from the University of Pennsylvania last week at IDWeek 2014 in Philadelphia.
16 October 2014 | HIVandHepatitis.com
"On good days, adhering to my pill is a positive affirmation of my life, an exercise in self-love. On bad days, it's just a pill I need to swallow, not terribly bitter but as mildly annoying as having to shave or tie my shoelaces every day. It's yet another thing to add to my list of things, but I do it anyway." Josh Kruger on his ambiguous relationship to HIV treatment.
01 October 2014 | TheBody.com
India could run out of a critical medicine in its free HIV/AIDS drugs program in three weeks due to bureaucratic bungling, a senior government official said, leaving more than 150,000 sufferers without life-saving drugs for about a month.
01 October 2014 | Reuters
Among HIV-positive patients, concurrent use of medications is associated with nonadherence to antiretroviral therapy (ART), according to research published in the Journal of Managed Care & Specialty Pharmacy.
29 September 2014 | Pharmacy Times
HIV drugs which only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of ‘pill fatigue’.
15 September 2014 | University of Liverpool press release
The Uganda Coalition for Access to Essential Medicine (UCAEM) has asked government to withdraw and cease use of non-film coated tenofovir and lamivudine, dubbing the drug combination as notoriously bitter. "People living with HIV will more likely stop taking treatment than use this medicine," said Margaret Happy, the advocacy officer of the International Community of Women in East Africa (ICWEA).
10 September 2014 | Allafrica.com